Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Lockheed Martin Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Lockheed Martin Corporation trades at $527.82 (market cap $120.64B). The key difference: Lockheed Martin Corporation is far larger — about 3× Alnylam Pharmaceuticals, Inc.'s market cap, and Lockheed Martin Corporation pays a 2.64% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | LMT | |
|---|---|---|
Market Cap | $39.89B | $120.64B |
Sector | Health | Industrials |
52-Week High | $491.22 | $676.70 |
52-Week Low | $278.09 | $410.74 |
Enterprise Value | $38.15B | $139.44B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Lockheed Martin (LMT) trades at $523.22, up 0.96% on the day, with a bearish technical signal despite recent positive momentum. The company reported $75.05B in 2025 revenue but missed Q1 2026 EPS estimates. Strong analyst consensus favors a buy rating with a $627.50 price target, supported by a $3.45 dividend and robust defense contracts, including a recent $3.5B naval acquisition and European missile production deals.
Outlook remains positive due to elevated defense spending and a $186.4B backlog, though risks include execution challenges and geopolitical volatility. The stock presents value with a P/E of 25.34 and high ROE of 67.64%, but investors should monitor earnings consistency and debt levels, which have risen to 36.26% of assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
